See more : Zaptec AS (ZAP.OL) Income Statement Analysis – Financial Results
Complete financial analysis of EnWave Corporation (NWVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EnWave Corporation, a leading company in the Industrial – Machinery industry within the Industrials sector.
You may be interested
- Qomolangma Acquisition Corp. (QOMOU) Income Statement Analysis – Financial Results
- Lemonade, Inc. (LMND) Income Statement Analysis – Financial Results
- CSBC Corporation (2208.TW) Income Statement Analysis – Financial Results
- UPC Technology Corporation (1313.TW) Income Statement Analysis – Financial Results
- Ayyan Investment Company (2140.SR) Income Statement Analysis – Financial Results
EnWave Corporation (NWVCF)
About EnWave Corporation
EnWave Corporation designs, constructs, markets, licenses, installs, and sells vacuum-microwave machinery for the food, cannabis, and biomaterial dehydration industries in Canada and the United States. It offers radiant energy vacuum (REV) dehydration platforms, such as nutraREV and quantaREV to dehydrate fruits, vegetables, herbs, dairy products, ready-to-eat meals, instant baked goods, cannabis products, nutraceuticals, pharmaceuticals, and meats and seafood. The company also provides REV platforms for pharmaceutical industry, including powderREV; and freezeREV for the dehydration of biomaterial and pharmaceutical products. In addition, it manufactures and sells cheddar, gouda, bacon cheddar, parmesan garlic, black pepper, white cheddar, and pepper jack flavors. The company sells its products through various direct customer relationships, brokers, distributors, and retailers; its online store, mooncheese.com; and Amazon.com, Inc. EnWave Corporation was founded in 1999 and is headquartered in Delta, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.18M | 11.36M | 23.70M | 26.48M | 32.88M | 42.84M | 22.83M | 15.95M | 14.93M | 5.87M | 4.55M | 5.45M | 486.90K | 217.02K | 131.05K | 496.56K | 74.04K | 74.23K | 37.31K | 1.40K | 6.24K | 282.62K | 0.00 | 6.53K | 1.00 | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 5.52M | 6.93M | 17.41M | 19.31M | 24.11M | 29.24M | 13.92M | 11.65M | 10.38M | 4.69M | 3.98M | 3.80M | 971.29K | 0.00 | 10.63K | 502.50K | 0.00 | 22.67K | 46.64K | 0.00 | 0.00 | 102.07K | 0.00 | 0.00 | -148.39K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.66M | 4.43M | 6.29M | 7.17M | 8.77M | 13.61M | 8.91M | 4.30M | 4.55M | 1.18M | 578.36K | 1.65M | -484.39K | 217.02K | 120.42K | -5.94K | 74.04K | 51.56K | -9.33K | 1.40K | 6.24K | 180.55K | 0.00 | 6.53K | 148.39K | 100.00K | 100.00K | 100.00K |
| Gross Profit Ratio | 32.50% | 39.01% | 26.54% | 27.07% | 26.67% | 31.76% | 39.04% | 26.95% | 30.47% | 20.09% | 12.70% | 30.33% | -99.48% | 100.00% | 91.89% | -1.20% | 100.00% | 69.46% | -25.00% | 100.00% | 100.00% | 63.88% | 0.00% | 100.00% | 14,838,600.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 1.49M | 1.58M | 2.18M | 1.88M | 1.99M | 1.69M | 1.21M | 1.14M | 1.66M | 1.39M | 1.59M | 2.67M | 2.54M | 2.51M | 1.73M | 869.46K | 766.06K | 621.77K | 174.77K | 113.12K | 37.16K | 76.30K | 6.38K | 349.96K | 669.73K | 600.00K | 0.00 | 0.00 |
| General & Administrative | 2.59M | 2.74M | 5.65M | 5.92M | 6.85M | 6.15M | 2.98M | 2.96M | 2.39M | 2.35M | 2.73M | 3.11M | 1.83M | 1.77M | 1.49M | 1.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.47M | 1.40M | 5.47M | 4.65M | 6.47M | 5.79M | 3.73M | 2.16M | 793.00K | 719.00K | 1.17M | 979.04K | 424.64K | 279.91K | 162.76K | 104.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.06M | 4.14M | 11.12M | 10.57M | 13.32M | 11.94M | 6.72M | 5.12M | 3.18M | 3.07M | 3.89M | 4.09M | 2.26M | 2.05M | 1.65M | 1.12M | 1.39M | 870.74K | 183.09K | 194.99K | 77.98K | 136.86K | 146.99K | 484.07K | 973.32K | 900.00K | 100.00K | 0.00 |
| Other Expenses | -2.90M | 0.00 | -11.00K | -1.12M | -1.37M | 391.00K | 0.00 | 0.00 | -178.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 468.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.66M | 5.73M | 13.28M | 11.32M | 13.94M | 14.02M | 8.50M | 7.15M | 6.06M | 5.88M | 7.23M | 9.14M | 5.95M | 5.19M | 3.38M | 1.99M | 2.15M | 1.49M | 368.91K | 308.11K | 115.14K | 213.16K | 153.37K | 834.02K | 1.79M | 1.60M | 100.00K | 0.00 |
| Cost & Expenses | 8.18M | 13.00M | 30.70M | 30.63M | 38.05M | 43.26M | 22.42M | 18.80M | 16.44M | 10.56M | 11.20M | 12.93M | 6.92M | 5.19M | 3.39M | 2.49M | 2.15M | 1.52M | 415.54K | 308.11K | 115.14K | 315.23K | 153.37K | 834.02K | 1.64M | 1.60M | 100.00K | 0.00 |
| Interest Income | 211.00K | 185.00K | 144.00K | 7.00K | 116.00K | 179.00K | 60.00K | 0.00 | 0.00 | 107.00K | 111.38K | 115.35K | 158.94K | 133.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 140.00K | 128.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 81.00K | 277.43K | 126.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.16M | 1.12M | 1.10M | 2.51M | 2.04M | 2.02M | 1.98M | 1.96M | 2.30M | 2.23M | 1.75M | 2.14M | 1.35M | 755.13K | 88.81K | 52.98K | 30.71K | 15.89K | 16.79K | 16.69K | 16.93K | 78.80K | 108.25K | 137.58K | 148.39K | 100.00K | 0.00 | 0.00 |
| EBITDA | -1.05M | -334.00K | -1.43M | -1.64M | -4.75M | 1.61M | 2.38M | -885.00K | 807.00K | -2.46M | -3.26M | -5.22M | -5.09M | -4.22M | -3.17M | -1.94M | -2.05M | -1.43M | -361.44K | -290.02K | -91.97K | 46.19K | -45.11K | -689.92K | -1.49M | -1.40M | 0.00 | 100.00K |
| EBITDA Ratio | -12.83% | -2.94% | -19.02% | -3.63% | -9.62% | 5.77% | 14.30% | -4.91% | 7.49% | -40.17% | -105.09% | -95.88% | -940.08% | -1,942.54% | -2,417.54% | -391.26% | -2,764.02% | -1,919.67% | -968.72% | -20,715.79% | -1,474.29% | 16.34% | 0.00% | -10,570.22% | -149,466,000.00% | -1,400.00% | 0.00% | 100.00% |
| Operating Income | 0.00 | -1.48M | -7.06M | -3.48M | -5.20M | 448.00K | 1.29M | -2.75M | -1.20M | -4.59M | -6.54M | -7.37M | -6.43M | -4.97M | -3.26M | -2.00M | -2.08M | -1.44M | -378.23K | -306.71K | -108.90K | -32.61K | -153.37K | -827.50K | -1.64M | -1.50M | 0.00 | 100.00K |
| Operating Income Ratio | 0.00% | -13.06% | -29.77% | -13.13% | -15.82% | 1.05% | 5.63% | -17.22% | -8.02% | -78.20% | -143.55% | -135.25% | -1,320.54% | -2,290.49% | -2,485.31% | -401.93% | -2,805.50% | -1,941.08% | -1,013.73% | -21,907.79% | -1,745.74% | -11.54% | 0.00% | -12,678.06% | -164,304,500.00% | -1,500.00% | 0.00% | 100.00% |
| Total Other Income/Expenses | -2.35M | -95.00K | 269.00K | -1.36M | 182.00K | -683.00K | -816.00K | -137.00K | -328.00K | -297.00K | -91.00K | -525.62K | -340.09K | 132.04K | 468.00 | 0.00 | -3.85K | -323.00 | 150.00K | 0.00 | 0.00 | 3.00K | -49.16K | -171.92K | 257.45K | 300.00K | 0.00 | -100.00K |
| Income Before Tax | -2.35M | -1.58M | -6.96M | -4.83M | -5.02M | -1.10M | -407.00K | -2.99M | -1.84M | -4.99M | -6.99M | -8.01M | -6.77M | -4.84M | -3.26M | 0.00 | -2.08M | -1.44M | -228.23K | 0.00 | 0.00 | -29.61K | -202.53K | -999.42K | -1.39M | -1.20M | 0.00 | 0.00 |
| Income Before Tax Ratio | -28.73% | -13.90% | -29.34% | -18.25% | -15.27% | -2.56% | -1.78% | -18.72% | -12.30% | -85.09% | -153.50% | -147.01% | -1,390.39% | -2,229.92% | -2,484.96% | 0.00% | -2,810.71% | -1,941.52% | -611.70% | 0.00% | 0.00% | -10.48% | 0.00% | -15,312.06% | -138,559,300.00% | -1,200.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | -28.00K | -707.00K | -579.00K | 889.00K | 538.00K | 542.00K | 606.00K | 3.75M | 277.43K | -119.50K | 340.09K | -133.40K | -28.61K | -23.14K | -29.17K | -30.71K | -11.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -2.40M | -6.51M | -6.93M | -4.13M | -4.44M | -1.99M | -1.30M | -3.39M | -2.12M | -8.66M | -6.99M | -7.89M | -6.77M | -4.84M | -3.23M | -1.97M | -2.05M | -1.41M | -216.25K | -306.71K | -108.90K | -29.61K | -202.53K | -999.42K | -1.39M | -1.20M | 0.00 | 0.00 |
| Net Income Ratio | -29.31% | -57.31% | -29.22% | -15.58% | -13.51% | -4.64% | -5.67% | -21.25% | -14.16% | -147.55% | -153.50% | -144.82% | -1,390.39% | -2,229.03% | -2,463.12% | -397.27% | -2,771.30% | -1,900.15% | -579.59% | -21,907.79% | -1,745.74% | -10.48% | 0.00% | -15,312.06% | -138,559,400.00% | -1,200.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.06 | -0.06 | -0.04 | -0.04 | -0.02 | -0.01 | -0.04 | -0.02 | -0.10 | -0.08 | -0.10 | -0.09 | -0.07 | -0.06 | -0.05 | -0.06 | -0.05 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.06 | -0.09 | -0.09 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | -0.06 | -0.06 | -0.04 | -0.04 | -0.02 | -0.01 | -0.04 | -0.02 | -0.10 | -0.08 | -0.10 | -0.09 | -0.07 | -0.06 | -0.05 | -0.06 | -0.05 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.06 | -0.09 | -0.09 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 110.55M | 110.35M | 111.57M | 111.26M | 105.44M | 99.51M | 90.80M | 90.38M | 84.47M | 82.76M | 77.32M | 73.10M | 66.63M | 53.38M | 41.26M | 35.41M | 30.03M | 25.72M | 22.64M | 20.05M | 18.18M | 16.11M | 16.11M | 16.11M | 13.73M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 0.00 | 110.55M | 110.35M | 111.57M | 111.26M | 105.44M | 99.51M | 90.80M | 90.38M | 84.47M | 82.76M | 77.32M | 73.10M | 66.63M | 53.38M | 41.26M | 35.41M | 30.03M | 25.72M | 22.64M | 20.05M | 18.18M | 16.11M | 16.11M | 16.11M | 13.73M | 0.00 | 0.00 |
EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration
VANCOUVER, British Columbia, July 09, 2021 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announces that it has signed a material transfer agreement (“MTA”) with MedImmune Limited, an affiliate of AstraZeneca AB (LSE/STO/Nasdaq: AZN) (“AZ”), to facilitate...
EnWave Corporation (NWVCF) CEO Brent Charleton on Q2 2021 Results - Earnings Call Transcript
EnWave Corporation (NWVCF) CEO Brent Charleton on Q2 2021 Results - Earnings Call Transcript
EnWave Corporation (NWVCF) CEO Brent Charleton on Q1 2021 Results - Earnings Call Transcript
EnWave Corporation (NWVCF) CEO Brent Charleton on Q1 2021 Results - Earnings Call Transcript
Where to Put $1,000 In 2021
These two cannabis stocks have risk, but they also have growing sales.
These 3 Stocks Could Turn Your $600 Stimulus Check Into Much More
These stocks offer a mix of speculation and steady growth.
EnWave Corporation (NWVCF) CEO Brent Charleton on Q4 2020 Results - Earnings Call Transcript
Seeking Alpha Transcripts | Technology EnWave Corporation (NWVCF) CEO Brent Charleton on Q4 2020 Results - Earnings Call Transcript Dec. 21, 2020 2:32 PM ET | | About: EnWave Corporation (NWVCF) by: SA Transcripts Subscribers Only Earning Call Audio EnWave...
Source: https://incomestatements.info
Category: Stock Reports